Western Standard Hedges With Biotech Trade – ValueWalk Premium

Western Standard Hedges With Biotech Trade

Eric Andersen and Robert Wallendorf, portfolio manager and director of research respectively at Western Standard Partners, have a portfolio objective in 2018. The Los Angeles-based long/short hedge fund, up 2.6% as of March, is beating the Russell 2000, which is down 0.1%, through stock selection and creating a “margin of safety,” borrowing a technique from legendary value investor Seth Klarman. In their March letter to investors reviewed by ValueWalk they explain their reasons for a short hedge.

“The partnership’s goal for the second quarter of . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds. 📈

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

Sign up now. 👇

CLICK HERE TO TRY IT OUT

 

0